Filter News
Area of Research
News Topics
- (-) Biomedical (4)
- (-) Fusion (1)
- (-) Physics (1)
- (-) Transportation (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (1)
- Artificial Intelligence (8)
- Bioenergy (1)
- Biology (2)
- Chemical Sciences (2)
- Climate Change (3)
- Computer Science (11)
- Cybersecurity (13)
- Energy Storage (1)
- Environment (2)
- Exascale Computing (1)
- Frontier (1)
- Grid (2)
- High-Performance Computing (1)
- Isotopes (13)
- Machine Learning (6)
- Materials (2)
- Materials Science (2)
- National Security (22)
- Neutron Science (2)
- Nuclear Energy (4)
- Partnerships (4)
- Quantum Science (1)
- Security (8)
- Space Exploration (1)
- Sustainable Energy (1)
Media Contacts
Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.
As vehicles gain technological capabilities, car manufacturers are using an increasing number of computers and sensors to improve situational awareness and enhance the driving experience.
A partnership of ORNL, the Tennessee Department of Economic and Community Development, the Community Reuse Organization of East Tennessee and TVA that aims to attract nuclear energy-related firms to Oak Ridge has been recognized with a state and local economic development award from the Federal Laboratory Consortium.
Nine student physicists and engineers from the #1-ranked Nuclear Engineering and Radiological Sciences Program at the University of Michigan, or UM, attended a scintillation detector workshop at Oak Ridge National Laboratory Oct. 10-13.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.